SCHEMBL17570852

SCHEMBL17570852

Cn1c2ccccc2n2c3ncccc3nc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.41
HTR3E A5X5Y0 2/20 0.41
HTR3B O95264 2/20 0.41
HTR3A P46098 2/20 0.41
HTR3D Q70Z44 2/20 0.41
HTR3C Q8WXA8 2/20 0.41
PDE2A O00408 1/20 0.41
HTR1A P08908 1/20 0.41
HTR2C P28335 1/20 0.41
ADORA1 P30542 2/20 0.41
EGFR P00533 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PDE10A Q9Y233 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
PKM P14618 1/20 0.40
MAPT P10636 2/20 0.39
ALDH1A1 P00352 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17849983 0.87 ATM (0.45) ATMHTR3EHTR3BHTR3AHTR3D
SCHEMBL19486455 0.81 SMN1; SMN2 (0.43) ATMHTR3EHTR3BHTR3AHTR3D
SCHEMBL12799837 0.79 ATM (0.53) ATMADORA1EGFRMEN1KMT2A
SCHEMBL18083374 0.77 ADORA1 (0.42) ATMHTR3EHTR3BHTR3AHTR3D
SCHEMBL18083287 0.75 SMN1; SMN2 (0.55) ATMMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL13852978 0.72 HTR3E (0.39) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL16441948 0.72 KMT2A (0.43) ATMMEN1KMT2APDE10ASMN1; SMN2
SCHEMBL17993517 0.71 KDM4E (0.47) ATMHTR3EHTR3BHTR3AHTR3D
SCHEMBL20929588 0.71 MEN1 (0.47) ATMPDE2AADORA1EGFRMEN1
SCHEMBL17849975 0.71 ATM (0.53) ATMPDE2AADORA1EGFRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10968229-B2 Seven-membered ring compounds IDEMITSU KOSAN CO., LTD. (JP) 2021-04-06 US disclosed
US-20190245152-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2019-08-08 US disclosed
EP-2993215-B1 Azabenzimidazo[2,1-a]benzimidazoles for electronic applications IDEMITSU KOSAN CO (JP) 2019-06-19 EP disclosed
US-20190119291-A1 SEVEN-MEMBERED RING COMPOUNDS IDEMITSU KOSAN CO., LTD. (JP) 2019-04-25 US disclosed
EP-3034506-A1 4-functionalized carbazole derivatives for electronic applications Idemitsu Kosan Co., Ltd (JP) 2016-06-22 EP disclosed
EP-2993215-A1 Azabenzimidazo[2,1-a]benzimidazoles for electronic applications Idemitsu Kosan Co., Ltd. (JP) 2016-03-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119291-A1 SEVEN-MEMBERED RING COMPOUNDS MCM7, XPO7, LUC7L2 ATM 4103/4885HTR3E 4682/4885HTR3B 4619/4885
US-10968229-B2 Seven-membered ring compounds MCM7, XPO7, LUC7L2 ATM 4103/4885HTR3E 4682/4885HTR3B 4619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.